We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 15, 2020

Coadministration of CD19- and CD20-Targeted CAR-T Cells for Relapsed/Refractory DLBCL

Cancer Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Medicine
Phase II Trial of Co-Administration of CD19- and CD20-Targeted Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Large B Cell Lymphoma
Cancer Med 2020 Jul 01;[EPub Ahead of Print], W Sang, M Shi, J Yang, J Cao, L Xu, D Yan, M Yao, H Liu, W Li, B Zhang, K Sun, X Song, C Sun, J Jiao, Y Qin, T Sang, Y Ma, M Wu, X Gao, H Cheng, Z Yan, D Li, H Sun, F Zhu, Y Wang, L Zeng, Z Li, J Zheng, K Xu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading